Caprock Group’s RenovoRx RNXT Stock Holding History

Caprock Group’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64.6K	Hold	63,940	–	–	﹤0.01%	1096
2025 Q4	$53.7K	Buy	+63,940	New	+$64K	﹤0.01%	1175

Other funds holding RNXT

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

NPT

Nixon Peabody Trust Boston, Massachusetts $1.26B AUM 24.14% 1-Year Est. Return

CPIG

Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return

Caprock Group's RNXT Position: Q1 2026 in Review

Caprock Group held its RenovoRx (RNXT) position steady in Q1 2026 at 63,940 shares worth $64.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Caprock Group first reported a position in RNXT in Q4 2025 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold RNXT as of Q1 2026.

Caprock Group held 63,940 shares of RenovoRx worth $64.6K as of Q1 2026.
Caprock Group left its RenovoRx share count unchanged in Q1 2026.
RenovoRx made up ﹤0.01% of Caprock Group's portfolio in Q1 2026, its #1096 holding.
Caprock Group first reported a position in RenovoRx in Q4 2025 and has held it in 2 quarters since.
31 funds tracked by Wall St. Rank held RenovoRx as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.